Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years

BACKGROUND: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawton, Annie, Goodwin, Elizabeth, Boddy, Kate, Freeman, Jennifer, Thomas, Sarah, Chataway, Jeremy, Green, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Topical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894952/
https://www.ncbi.nlm.nih.gov/pubmed/32880511
http://dx.doi.org/10.1177/1352458520954172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894952/
https://www.ncbi.nlm.nih.gov/pubmed/32880511
http://dx.doi.org/10.1177/1352458520954172

Ejemplares similares